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shortening and higher mean wedge pressure. At follow-up 
of 7.4  8 2.1 months, the LVMI and New York Heart Associa-
tion class remained higher in patients with non-physiologic 
hypertrophy.  Conclusions: Our study suggests a different 
quality of hypertrophies in patients with aortic stenosis, 
where myocardial fibrosis seems to be the critical abnormal-
ity that differentiates adaptive from maladaptive response 
to increased afterload.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Aortic valve stenosis (AS) is the most frequent expres-
sion of valvular heart diseases in the western population, 
and left ventricular hypertrophy (LVH) is a major com-
pensatory mechanism in response to pressure overload 
 [1,  2] . The hypertrophy normalizes LV wall stress and 
maintains normal LV ejection  [3] . However, recent stud-
ies questioned the beneficial role of LVH in AS, suggest-
ing that increased LV mass is a predictor of LV dysfunc-
tion  [4, 5] . Impaired systolic and diastolic LV function 
was independently related to mortality after aortic valve 
replacement for aortic stenosis  [6] .
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 Abstract 
 Aim: It was the aim of our study to determine whether myo-
cardial fibrosis influences physiologic or non-physiologic 
left ventricular (LV) hypertrophy in severe aortic stenosis. 
 Methods: Myocardial fibrosis was evaluated using speci-
mens taken from the ventricular septum in 79 patients sub-
mitted to aortic valve replacement because of symptomatic 
aortic stenosis. Patients were considered to have physiolog-
ic LV hypertrophy if end-systolic wall stress, evaluated by 
echocardiography, was  ! 90 kdyn/cm 2 , while those with end-
systolic wall stress  1 90 kdyn/cm 2 were considered to have 
non-physiologic hypertrophy.  Results: Fibrosis tissue mass 
index was significantly inversely related with LV fractional 
shortening and directly related with LV diastolic and systolic 
diameter and LV mass index (LVMI). Patients with non-phys-
iologic hypertrophy (n = 24) had a higher LVMI due to larger 
LV diastolic and systolic diameters with thinner wall, result-
ing in lower relative wall thickness. These patients had a 
higher fibrosis tissue mass index and impaired LV systolic 
and diastolic functions, as suggested by lower LV fractional 
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 This deleterious effect of the hypertrophy is due to the 
presence of myocyte degeneration and myocardial fibro-
sis in the hypertrophic ventricle. Myocardial fibrosis 
seems to be the major determinant of both diastolic and 
systolic functions in aortic stenosis: myocardial fibrosis 
increases, LV end-diastolic pressure increases and ejec-
tion fraction decreases  [7] . The increment in LV mass sec-
ondary to the increase in afterload might not be able to 
normalize wall stress and maintain LV function in the 
presence of myocardial fibrosis  [8, 9] .
 Our aim was to determine whether the presence of 
myocardial fibrosis influences physiologic or non-physi-
ologic hypertrophic response in severe aortic stenosis.
 Methods 
 Study Group 
 From January 1998 to December 2005, 896 patients underwent 
aortic valve replacement at the University Hospital of Verona. 
Among them, 81 patients with high-quality echocardiographic 
examination performing M-mode and Echo-Doppler quantita-
tive analyses, without previous myocardial infarction, critical 
coronary artery disease, prior cardiac surgery or aortic insuffi-
ciency  grade  1 1 were enrolled by a single surgeon (G.F.) to carry 
out a biopsy of the interventricular septum. 
 The following types of prostheses were placed using a previ-
ously described procedure  [10] : Hancock biological valve in 46 
patients (57%), Sorin Bicarbon mechanical valve in 13 patients 
(16%), Carbomedics mechanical valve in 10 patients (12%) and 
Edwards Perimount pericardial valve in 12  patients (15%). The 
sizes of the implanted prostheses were as follows: 21 mm in 18 
(22%), 23 mm in 46 (57%), 25 mm in 15 (19%) and 27 mm in 2 pa-
tients (3%).
 Patients were divided into two groups according to end-systolic 
wall stress (calculated as described below): patients with end-sys-
tolic wall stress  ^  90 kdyn/cm 2 were considered to have physiolog-
ic hypertrophy, while those with end-systolic wall stress  1 90 kdyn/
cm 2 were considered to have non-physiologic hypertrophy  [8] .
 A clinical and echocardiographic follow-up was obtained in 
each patient at 7.4  8 2.1 months (range 3.5–11.4) after surgery.
 Echocardiography 
 All patients underwent an M-mode, bidimensional and
Doppler echocardiographic study before surgery. All echocardio-
graphic measurements were performed according to the Ameri-
can Society of Echocardiography  [11] . LV end-diastolic diameter 
(LVEDD), LV end-systolic diameter (LVESD), LV diastolic and 
systolic septal and inferior wall thickness (LVPWTd and
LVPWTs) were measured by M-mode echocardiography. LV frac-
tional shortening (LVFS) was calculated as: 100   (LVEDD – 
LVESD)/LVEDD. LV mass was calculated according to the De-
vereux formula  [12] and indexed by body surface area (LV mass 
index, LVMI). Relative wall thickness (RWT) was calculated ac-
cording to the following formula: RWT = (2   LVPWTd)/LV in-
ternal diastolic diameter. LV end-systolic wall stress (ESWS)
was calculated as: ESWS = 0.334   P   LVESD/[LVPWTs   (1 + 
LVPWTs/LVESD)], where P is the LV peak systolic pressure cal-
culated as the sum of the systolic blood pressure taken by sphyg-
momanometry plus peak aortic gradient evaluated by Doppler 
 [13] . The degree of AS was assessed by estimation of Doppler peak 
gradient, Doppler mean gradient and aortic valve area, calculated 
using the standard formula of continuity equation.
 Heart Catheterization 
 All patients underwent selective coronary angiography. Fifty-
seven patients (37 with physiologic hypertrophy, 20 with non-
physiologic hypertrophy) underwent right heart catheterization 
with measurements of right ventricular and pulmonary artery 
pressure and mean pulmonary wedge pressure.
 Morphological Study 
 Specimens were taken from the ventricular septum in a man-
ner similar to surgical subaortic myectomy. The biopsy material 
was preserved in 10% formaldehyde solution overnight and then 
totally embedded in paraffin. It was cut into 2-m-thick sections 
which were stained with haematoxylin-eosin and Masson’s tri-
chrome. The amount of myocardial fibrous tissue was determined 
by point counting using a 10  ! 10 grid at a total magnification of 
 ! 100  [14, 15] . A fibrosis index (FI) was calculated by dividing the 
sum of the fibrotic areas of the section by that of the total tissue 
area and was expressed as percentage, as described by Tanaka et 
al.  [16] . According to the FI, the patients were classified as having 
no or mild fibrosis ( ! 20%), moderate fibrosis (21–50%) or severe 
fibrosis ( 1 50%). Fibrous tissue mass index (FTMI) was expressed 
as FI  ! LVMI/100.
 Statistical Analysis 
 Data are expressed as mean  8 1 standard deviation. Differ-
ences between continuous variables among groups were analysed 
by the two-tailed unpaired t test. Event frequency among the 
groups of patients was analysed by the   2 test. Linear regression 
analysis was used to evaluate the relations between variables. A
p value  ! 0.05 was considered statistically significant. StatView 
release 5.0 software (SAS Institute Inc., copyright 1992–1998)
was used for statistical analysis.
 Results 
 Patients 
 There were 2 in-hospital deaths (2%) due to low car-
diac output syndrome, and these patients were excluded 
from the study. In the early postoperative period, there 
was 1 cerebrovascular event, 14 low cardiac output syn-
dromes and 3 acute renal failures that required haemodi-
alysis for a few days.
 Table 1 summarizes demographic, echocardiographic, 
haemodynamic and morphologic parameters in the 
whole study population. The mean age was 71.2  8 9.9 
years; 47 patients (59.5%) were  1 70 years of age and 37 
(46.8%) were men. The mean New York Heart Associa-
tion (NYHA) functional status was 2.5  8 0.7: 8 patients 
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(10.1%) were in class I, 27 (34.1%) in class II, 41 (51.8%) in 
class III, and 3 (3.7%) in class IV.
 The mean FTMI was 62.5  8 37.9 g/m 2 . Twenty-two 
patients (27.8%) had mild myocardial fibrosis, with a 
mean FTMI of 17.4  8 5.1 g/m 2 ; 45 patients (57.0%) had 
moderate myocardial fibrosis, with a mean FTMI of 56.6 
 8 12.7 g/m 2 ; 12 patients (15.1%) had severe myocardial 
fibrosis, with a mean FTMI of 103.5  8 28.5 g/m 2 .
 Cardiac Function, Hypertrophy and Morphology 
 In the whole study population, LVFS was inversely re-
lated to ESWS, LVMI and FTMI ( fig. 1 ). ESWS and LV 
remodelling, expressed by LVMI, end-diastolic volume 
and end-systolic volume, were significantly related to 
FTMI ( fig. 2 ).
 Fifty-five patients had physiologic hypertrophy, while 
24 patients had non-physiologic hypertrophy. The char-
acteristics of the patients with physiologic and non-phys-
iologic hypertrophy are reported in  table  1 . No differ-
ences were found in the mean age, sex, history of hyper-
tension or diabetes. Patients with non-physiologic LVH 
showed a higher NYHA functional class (2.8  8 0.7 vs. 2.4 
 8 0.7; p = 0.016), a lower peak (73  8 16 vs. 82  8 17 mm 
Hg; p = 0.025) and mean (46  8 10 vs. 53  8 13 mm Hg;
p = 0.01) aortic gradient and a higher aortic valve area 
(0.44  8 0.10 vs. 0.37  8 0.08 cm 2 /m 2 ; p = 0.0012).
 Patients with non-physiologic hypertrophy had a 
higher LVMI (215  8 39 vs. 183  8 33 g/m 2 ; p = 0.0005). 
However, this higher LV mass was due to larger LV diam-
eters (LVEDD 54.3  8 3.0 vs. 46.9  8 4.6 mm; p  ! 0.0001) 
with thinner wall (LVPWTd 12.5  8 1.8 vs. 13.5  8 1.4 
mm; p = 0.015), resulting in lower RWT (0.46  8 008 vs. 
0.58  8 0.08; p  ! 0.0001). These patients had more impor-
tant fibrosis (FTMI 88.3  8 45.8 vs. 51.1  8 28.7 g/m 2 ;
Table 1. D emographic, echocardiographic, haemodynamic and morphologic parameters of the study population
All patients
(n = 79)
Physiologic hyper-
trophy (n = 55)
Non-physiologic
hypertrophy (n = 24)
p
Age, years 71.289.9 70.5810.2 72.789.1 0.32
Males/females 37/42 10/14 27/28 n.s.
Diabetes 14 11 3 n.s.
Hypertension 22 14 8 n.s.
NYHA class 2.580.7 2.480.7 2.880.7 0.016
LVEDD, mm 49.185.4 46.984.6 54.383.0 <0.0001
LVESD, mm 31.486.0 28.885.0 37.583.0 <0.0001
LVPWTd, mm 13.281.6 13.581.4 12.581.8 0.015
LVPWTs, mm 18.382.2 18.982.0 16.881.8 <0.0001
LVSWTd, mm 14.881.6 15.181.5 14.081.5 0.004
LVSWTs, mm 19.282.1 19.782.0 18.281.9 0.004
LVFS, % 36.487.5 38.987.0 30.985.5 <0.0001
RWT 0.5580.10 0.5880.08 0.4680.08 <0.0001
LVMI, g/m2 193838 183833 215839 0.0005
ESWS, kdyn/cm2 75.9825.0 62.3814.6 107.2811.2 <0.0001
Aortic PG, mm Hg 80817 82817 73816 0.025
Aortic MG, mm Hg 51812 53813 46810 0.016
Aortic VA, cm2/m2 0.3980.09 0.3780.08 0.4480.10 0.0012
RVSP, mm Hg (n = 57) 37.7810.8 34.486.8 43.9814.5 0.0011
RVDP, mm Hg (n = 57) 2.1982.45 1.582.0 3.682.7 0.0015
PASP, mm Hg (n = 57) 36.0811.7 32.6811.8 43.0819.6 0.0007
PADP, mm Hg (n = 57) 14.386.5 11.883.7 19.687.8 <0.0001
MWP, mm Hg (n = 57) 14.387.5 12.385.1 19.889.4 0.0002
FI, % 30.5814.7 26.6811.5 39.6817.3 0.0002
FTMI, g/m2 62.5838.8 51.1828.7 88.7846.3 <0.0001
n .s. = Not significant; LVSWTd = LV diastolic septal wall thickness; LVSWTs= LV systolic septal wall thickness; aortic PG =
aortic peak gradient; aortic MG = aortic mean gradient; aortic VA = index aortic valve area; RVSP = right ventricular systolic pressure; 
RVDP = right ventricular diastolic pressure; PASP = pulmonary artery systolic pressure; PADP = pulmonary artery diastolic pressure; 
MWP = mean wedge pressure.
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p  ! 0.0001) and impaired LV systolic and diastolic func-
tions, as suggested by lower LVFS (30.9  8 5.5 vs. 38.9  8 
7.0%; p  ! 0.0001) and higher mean wedge pressure (19.8 
 8 9.4 vs. 12.3  8 5.1 mm Hg; p = 0.0002) ( fig. 3 ).
 Follow-Up 
 At 7.4  8 2.1 months of follow-up, NYHA class de-
creased both in patients with physiologic (1.75  8 0.65) 
and non-physiologic hypertrophy (2.38  8 0.82). How-
ever, the reduction was larger in the first group, so that 
the NYHA class was lower in patients with physiologic 
hypertrophy at follow-up ( fig. 4 a). NYHA class was sig-
nificantly related to fibrosis, with a significant reduction 
at follow-up in patients with grade 1 and 2 FTMI, and not 
in those with grade 3 ( fig. 4 b).
 LV wall thickness decreased in both groups, whereas 
LV diameters remained constant (except for a small in-
crement in LVEDD in patients with physiologic hyper-
trophy). RWT decreased in patients with physiologic hy-
pertrophy, so that there was no difference between the 
two groups at follow-up. LVMI decreased both in patients 
with physiologic and in those with non-physiologic hy-
pertrophy, but remained significantly higher in the sec-
ond group. LVFS did not change ( table 2 ).
 Discussion 
 Our study shows that the hypertrophic response to 
pressure overload in aortic stenosis is related to myocar-
dial fibrosis. In the presence of myocardial fibrosis, the 
increment of LV mass is inadequate to normalize wall 
stress and to maintain normal LV function. Both myocar-
dial fibrosis and non-physiologic hypertrophy are nega-
tively related to NYHA class improvement after surgery.
 For a long time, LVH in aortic stenosis has been con-
sidered an adaptive process to normalize increased wall 
stress and to maintain LV function  [1–3, 17] . Several stud-
ies reported an inverse relationship between LV systolic 
wall stress and LV systolic function in patients with aortic 
stenosis  [18–20] . However, hypertrophy is not always an 
adaptive process  [4, 5] , because it is the consequence of a 
complex neuroendocrine pressure-induced process that 
may produce both beneficial adaptive and adverse mal-
adaptive hypertrophy  [21] . In our study, although there 
was a high correlation between LV systolic wall stress and 
LVFS, the LV mass was inversely related to LV function. 
The main reason why hypertrophy may represent a del-
eterious mechanism of compensation to elevated after-
load is apoptosis and myocardial fibrosis  [8, 15] .
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 Fig. 1. Relationship between LVFS and ESWS ( a ), LVMI ( b ) and 
FTMI ( c ) in the study patients.  
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 In our study, myocardial fibrosis was inversely related 
to LVFS and directly related to ESWS and LV remodelling, 
expressed by LVMI, end-diastolic volume and end-systolic 
volume. The better relationship between FTMI and LVM 
suggests that development of fibrosis is the main morpho-
logical alteration  [7] responsible for the larger increment in 
LV mass and LV dysfunction found in the group of patients 
with non-physiologic hypertrophy. These results are in 
line with those of Polyakova et al.  [22] who found a strong 
relation between progressive extracellular matrix fibrosis 
and LV systolic function in patients with AS.
 Myocardial fibrosis was larger in the group of patients 
with non-physiologic hypertrophy compared to patients 
with hypertrophy, adequate to normalize wall stress. In 
patients with physiologic hypertrophy, the increment in 
LV mass was related to the increment in wall thickness 
rather than to the increase in LV diameters (concentric 
hypertrophy): this increment in thickness normalizes 
wall stress and maintains LVFS. On the contrary, in pa-
tients with elevated stress, the larger increment in LV mass 
was secondary to a minor increase in LV thickness and a 
larger increase in LV diameters (eccentric hypertrophy).
 At follow-up, although a reduction in wall thickness 
was observed in both groups, LVMI remained higher, and 
ventricular systolic function (evaluated as LVFS) did not 
recover in patients with non-physiologic hypertrophy.
 It is possible that non-physiologic hypertrophy in the 
presence of a great LV mass may be the expression of 
more severe and prolonged LV systolic overload, with an 
increase in wall thickness without an increase in volume 
in the earlier phase, producing impairment of diastolic 
filling and increased LV filling pressures and resulting in 
an increment in LV volume in the later phase  [21] . In our 
study, this may be suggested by the higher mean pulmo-
nary capillary wedge pressure and right ventricular pres-
sure, the expression of LV diastolic dysfunction, in pa-
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 Fig. 2. Relationship between FTMI and ESWS ( a ), LVMI ( b ), LVEDD ( c ) and LVESD ( d ) in the study patients. 
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tients with non-physiologic hypertrophy. However, al-
though it was not possible to evaluate the duration of 
aortic stenosis in our patients, the age of patients with 
physiologic and non-physiologic hypertrophy did not 
differ, which was also reported by Serneri et al.  [8] . Fur-
thermore, in patients with non-physiologic hypertrophy, 
the peak and the mean aortic gradients were lower and 
the aortic valve area was larger compared to patients with 
physiologic hypertrophy.
 Alternatively, early activation of maladaptive growth 
signals and enzymes involved in collagen synthesis and 
degradation leading to deleterious remodelling could oc-
cur  [8, 23] . Serneri et al.  [8] have recently reported that in 
patients with aortic stenosis the presence of adequate hy-
pertrophy is related to the capacity of myocytes to gener-
ate growth factors, such as insulin-like growth factor 1 
and endothelin 1, able to increase contractility and wall 
thickness. On the contrary, non-physiologic hypertrophy 
might be related to the incapacity to produce these factors 
and to the generation of angiotensin II. In the study by 
Heymans et al.  [23] , transcript levels of both tissue in-
hibitors of metalloproteinases 1 and 2 were significantly 
related to the degree of fibrosis in AS patients. Thus, hy-
pertrophic growth of the heart is the result of a complex 
combinatorial action of various stimuli, which may have 
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Table 2.  NYHA class and echocardiographic parameters at fol-
low-up
Physiologic
hypertrophy
Non-physiologic
hypertrophy
p
NYHA class 1.780.6** 2.480.8* 0.0005
LVEDD, mm 47.684.8* 52.782.8 <0.0001
LVESD, mm 28.885.7 36.382.8 <0.0001
LVPWTd, mm 10.981.7** 11.581.8* n.s.
LVSWTd, mm 12.181.7** 12.782.2** n.s.
LVFS, % 39.589.2 30.985.2 <0.0001
RWT 0.4680.11** 0.4480.80 n.s.
LVMI, g/m2 136835** 180848** <0.0001
n .s. = Not significant; LVSWTd = LV diastolic septal wall 
thickness. * p < 0.01, ** p = 0.0001 versus baseline.
 Fig. 3. Mean  8 2 SD of FTMI, LVFS, LVMI and mean wedge pres-
sure (MWP) in patients with physiologic (black bar) and non-
physiologic hypertrophy (white bar ). 
 Fig. 4.  a NYHA class before and after surgery in patients with 
physiologic (black bar) and non-physiologic hypertrophy (white 
bar) ( *  p  ! 0.0001,  * *  p = 0.009 vs. baseline).  b NYHA class before 
and after surgery according to the grade of fibrosis ( *  p = 0.001, 
 * *  p  ! 0.0011 vs. baseline). Grey bar = Grade 1 FTMI; black bar = 
grade 2 FTMI; white bar = grade 3 FTMI. ANOVA: p = 0.03 before 
the operation, p = 0.002 after the operation. 
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different effects on gene expression and protein synthesis 
in different patients  [24] .
 Some limitations of our study should be considered. 
First, although our study shows a relationship between 
myocardial fibrosis, hypertrophy and LV function, it 
does not demonstrate that fibrosis is the cause of LV dys-
function. However, previous studies have reported myo-
cardial fibrosis as an anatomopathologic substrate to LV 
dysfunction. Secondly, we have enrolled only a small 
number of patients submitted to aortic valve surgery, op-
erated by one surgeon of our Division. Thirdly, all our 
patients were symptomatic; therefore, our results may not 
be attributed to asymptomatic patients with severe aortic 
stenosis.
 In conclusion, our study suggests the presence of a dif-
ferent quality of hypertrophy in patients with aortic ste-
nosis, in which myocardial fibrosis seems to be the criti-
cal abnormality to differentiate adaptive and maladaptive 
response to increased afterload.
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